Concentra Biosciences, LLC sent an unsolicited proposal to acquire Theseus Pharmaceuticals, Inc. (NasdaqGS:THRX) on November 24, 2023. As per consideration, Concentra Biosciences to acquire all outstanding shares of common stock of the Theseus Pharmaceuticals for $3.80 per share in cash, plus a contingent value right.
Theseus Pharmaceuticals, Inc.
Equities
THRX
US88369M1018
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+7.42% | 111B | |
+11.26% | 106B | |
-12.71% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.59% | 16.81B | |
+37.40% | 12.54B | |
-23.98% | 8.09B |